The table below shows ImmunityBio, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$304.94M
-$391.24M
-$366.76M
-$337.51M
-$274.42M
-$171.72M
Capital expenditure
$3.85M
$6.89M
$30.58M
$78.16M
$33.56M
$1.67M
Investing cash flow
-$149.80M
-$12.25M
-$30.47M
$27.30M
-$84.89M
-$19.81M
Dividends paid
-
-
-
-
IBRX operating cash flow (10-K history)
ImmunityBio, Inc. reported operating cash flow of -$304.94M for fiscal year 2025. That is up 22.1% from -$391.24M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$38.59M (FY 2016) to -$304.94M. Figures come from the company's audited annual reports as filed with the SEC.